Lilly released topline trial results for its oral GLP-1, orforglipron, on Thursday night, announcing an average weight loss of 12.4% and 12.4 kg among participants taking the highest dose (36mg).
The phase 3 ATTAIN-1 trial compared the daily pill against placebo at 72 weeks.
“In a key secondary endpoint, 59.6% of participants taking the highest dose of orforglipron lost at least 10% of their body weight, while 39.6% lost at least 15% of their body weight,” according to Lilly’s press release.
Patients taking the 12mg dose lost an average of 9.3% of their body weight, while those taking the 6mg dose lost an average of 7.8%.
By contrast, in the SURMOUNT-1 trial, Lilly’s injectable weight loss drug tirzepatide achieved average weight loss of approximately 15% at the 5mg dose, 19.5% at the 10 mg dose and 20.9% at the 15mg dose.
In May, Novo Nordisk filed an application to the FDA for its oral formulation of semaglutide in a 25mg dose, with participants reportedly achieving an average reduction of 13.6% of their body weight. A decision from the FDA is expected in Q4 this year.
Lilly says the detailed ATTAIN-1 results will be presented in September at the European Association for the Study of Diabetes Annual Meeting 2025 and published in a peer-reviewed journal.
Watch this space.
Listen to expert interviews.
Click to open in a new tab
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
